Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469110 | 0.80 | ALDH1A1 (0.44) | OPRM1OPRD1SLC6A2SLC6A3ESR1 | |
| SCHEMBL3084800 | 0.78 | CHRM2 (0.47) | OPRM1OPRD1SLC6A2SLC6A3ESR1 | |
| SCHEMBL8845652 | 0.77 | ESR1 (0.64) | OPRM1OPRD1SLC6A2SLC6A3ESR1 | |
| SCHEMBL3468550 | 0.74 | ESR1 (0.42) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL31291512 | 0.73 | KMT2A (0.69) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL3468157 | 0.73 | KMT2A (0.69) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL21381733 | 0.73 | OPRD1 (0.66) | OPRM1OPRD1CES2CES1NPC1 | |
| SCHEMBL30567959 | 0.73 | OPRD1 (0.66) | OPRM1OPRD1CES2CES1NPC1 | |
| SCHEMBL29090510 | 0.72 | CES2 (0.47) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL16265352 | 0.72 | ALDH1A1 (0.54) | SLC6A2SLC6A3ESR1PGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | OPRM1 160/4885OPRD1 110/4885SLC6A2 3943/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | OPRM1 160/4885OPRD1 110/4885SLC6A2 3943/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | OPRM1 211/4885OPRD1 235/4885SLC6A2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.